


PHARMACEUTICAL 2023

agios

AGIOS PHARMACEUTICALS INC. Rank 51 of 446





PHARMACEUTICAL 2023



agios

AGIOS PHARMACEUTICALS INC. Rank 51 of 446

The relative strengths and weaknesses of AGIOS PHARMACEUTICALS INC. are analyzed with respect to the market average, including all of its competitors. We analyzed all variables having an effect on the Economic Capital Ratio.

The greatest strength of AGIOS PHARMACEUTICALS INC. compared to the market average is the variable Liabilities, Current, increasing the Economic Capital Ratio by 56% points. The greatest weakness of AGIOS PHARMACEUTICALS INC. is the variable Other Revenues, reducing the Economic Capital Ratio by 16% points.

The company's Economic Capital Ratio, given in the ranking table, is 241%, being 197% points above the market average of 43%.

Input Variable	Value in 1000 USD
Assets, Current	832,772
Cost of Goods Sold	1,704
Intangible Assets	0
Liabilities, Current	62,629
Liabilities, Non-Current	75,275
Other Assets	382,959
Other Compr. Net Income	-11,337
Other Expenses	0
Other Liabilities	0
Other Net Income	157,246
Other Revenues	14,240
Property and Equipment	22,987
Research and Development	279,910
Selling, General and Administrative Expense	121,673

Output Variable	Value in 1000 USD
Assets	1,238,718
Liabilities	137,904
Expenses	403,287
Revenues	14,240
Stockholders Equity	1,100,814
Net Income	-231,801
Comprehensive Net Income	-237,470
Economic Capital Ratio	241%